RetinalGenix Technologies Inc. Files Q2 2025 10-Q

TL;DR

RTGN 10-Q filed for Q2 2025. Check financials.

AI Summary

RetinalGenix Technologies Inc. filed its 10-Q for the period ending June 30, 2025. The company, incorporated in Delaware, operates in the Surgical & Medical Instruments & Apparatus sector. Its principal business address is in Petaluma, California. The filing covers the second quarter of 2025.

Why It Matters

This filing provides investors with an update on RetinalGenix Technologies Inc.'s financial performance and operational status for the second quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly filing with no immediate red flags or significant new disclosures.

Key Numbers

• Q2 2025 — Reporting Period (Covers the second quarter of 2025.)
• 20250819 — Filing Date (Date the 10-Q was filed with the SEC.)

Key Players & Entities

• RetinalGenix Technologies Inc. (company) — Filer
• Petaluma, CA (location) — Business Address
• 3841 (industry_code) — Standard Industrial Classification
• 20250630 (date) — Period of Report

FAQ

Filing Documents

• form10-q.htm (10-Q) — 656KB
• ex31-1.htm (EX-31.1) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• 0001641172-25-024830.txt ( ) — 3635KB
• rtgn-20250630.xsd (EX-101.SCH) — 28KB
• rtgn-20250630_cal.xml (EX-101.CAL) — 35KB
• rtgn-20250630_def.xml (EX-101.DEF) — 122KB
• rtgn-20250630_lab.xml (EX-101.LAB) — 250KB
• rtgn-20250630_pre.xml (EX-101.PRE) — 206KB
• form10-q_htm.xml (XML) — 450KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3936890 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1450 North McDowell Boulevard , Suite 150 Petaluma , CA 94954 (Address of principal executive offices) (Zip Code) (415) 578-9583 (Registrant's telephone number, including area code) Not applicable (Former name, former address and former fiscal year, if changed since last report Securities registered pursuant to Section 12(b) of the Act: None Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No The number of shares of the issuer's common stock, $ 0.0001 par value per share, outstanding at August 18, 2025 was 18,604,961 . RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 ASSETS Current Assets Cash $ 839 $ 6,060 Total Current Assets 839 6,060 Equipment, net of accumulated depreciation of $ 307 and $ 251 at June 30, 2025 and December 31, 2024, respectively - 56 Operating lease right-of-use asset 5,554 6,835 Security deposit 1,995 1,995 TOTAL ASSETS $ 8,388 $ 14,946 LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities Current Liabilities Accounts payable and accrued liabilities $ 1,016,685 $ 922,083 Due to Sanovas 352,177 15,709 Due to related parties 547,148 467,793 Shareholders' notes payable 49,000 49,000 Lease liability – short term portion 988 988 Accrued interest payable 17,359 15,439 Total Current Liabilities 1,983,357 1,471,012 Lease liability – long term portion 6,196 6,544 Total liabilities 1,989,553 1,477,556 Commitments and contingencies - - Stockholders' Deficit: Preferred stock, $ 0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at December 31, 2024 and 2023 - - Common stock, $ 0.0001 par value; 80,000,000 shares authorized; 18,560,517 and 18,522,295 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1,856 1,852 Additional paid in capital 14,683,678 14,115,560 Stock subscription receivable - ( 150,000 ) Accumulated deficit ( 16,666,699 ) ( 15,430,022 ) Total Stockholders' Deficit ( 1,981,165 ) ( 1,462,610 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 8,388 $ 14,946 The accompanying notes are an integral part of these consolidated financial statements. 2 RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED For the three months ended June 30, 2025 2024 Revenues $ - $ - Operating expenses: General and administrative 383,729 368,738 Research and development 14,430 82,926 Stock-based compensation 250,189 211,009 Total operating expenses 648,348 662,673 Interest expense, net 1,070 960 Net loss $ ( 649,418 ) $ ( 663,633 ) Net loss per share - basic and diluted $ ( 0.034 ) $ ( 0.04 ) Weighted average number of common shares outstanding during the period- basic and diluted 18,326,587 17,863,564 The accompanying notes are an integral part of

View Full Filing

View this 10-Q filing on SEC EDGAR